Suzhou, China, 24 October 2021 - MicroPort Institute of Health (MIH), a division of MicroPort Scientific Corporation (MicroPort®), has officially launched its expansion project in Suzhou, China. The expansion is expected to provide additional platforms for comprehensive basic research to further strengthen the foundation for MicroPort® to develop its core businesses in the medium to long term.
With the completion of new infrastructures, such as MIH in Suzhou Industrial Park for basic biomedical and technology research, Miracle Point® Innovation Center in Zhangjiang Science City for technological commercialization, and the Super Factory in Jiaxing Science City for large-scale industrialization, MicroPort® will be able to create its own ecosystem with integrated MicroPort® innovation, supply, and industry chain within 50 km of the Yangtze River Delta (YRD). Together with the existing engineering research institute at MicroPort®’s headquarters, these sites are expected to act as the most direct and efficient vehicles to facilitate the commercialization of cutting-edge medical technologies.
Dr. Chengyun Yue, the First Vice President of Business Development and Project Management of MicroPort®, commented, “MIH is an important component of MicroPort®'s long-term strategy and unique business model. Through persistent effort, MicroPort® hopes to gain an advantageous position in the global medical industry in terms of intellectual property and technology. Meanwhile, MIH will further leverage the strengths of manufacturers, academic institutions, research centers, hospitals, and businesses in the YRD to create multiple comprehensive platforms for basic research as well as channels for international cooperation. This will also help attract and develop talents for the health industry, and at the same time create the right environment for top institutions and experts to carry out research and innovation.”
The healthcare industry has become a new engine of global economic development, with data showing that it contributes to more than 10% of GDP in most developed countries. Whilst in the United States, this percentage is close to 17%, in China, however, it is only 5%, and medical consumption per capita is less than half of the world average, with a gap compared to other major economies in the world. It is imperative to improve the level of basic healthcare research and innovation in China, and to reduce dependency on imports for high-end medical solutions.
Since it was founded in 2019, MIH has built several basic research platforms and product development centers for orthopedics through collaboration with MicroPort® Orthopedics Group headquarters. After this expansion project is completed, MIH will cover an area of 130,000 square meters, taking up nearly half of the effective working space of MicroPort® Suzhou campus. Following the direction of ‘intelligent, integrated, home-based and inclusive’ medical technology development, MIH conducts research into advanced biomaterials, brain-computer interfaces, wearable devices, neuromodulation, bioinformatics, artificial organs, micro and nano technologies, and artificial intelligence, with the aim of providing strategic support to the endeavors of MicroPort® Miracle Point® for the industrialization and commercialization of cutting-edge technologies.
About MicroPort Institute of Health (MIH)
MicroPort Institute of Health (MIH) is a division of MicroPort Scientific Corporation (00853.HK, MicroPort®), founded in 2019. MIH focuses on fundamental problems in the health industry, addressing difficulties in the medical field directly, and dedicating itself to developing total solutions for various diseases. Through its research and innovation capabilities, together with the expansion of its cooperation networks under the ‘dual circulation’ development pattern, MIH provides technical support for the whole industry chain to effectively address difficulties within the industry.